ROS1 and lung cancer: Furthermore, combination therapy with verteporfin and lorlatinib achieved a better anti-tumor effect in vivo compared to lorlatinib monotherapy, suggesting that YAP1 may mediate lorlatinib resistance of lung cancer cells (KTOR71), and simultaneous targeting of YAP1 and ROS1 may represent a more effective treatment strategy for patients with NSCLC harboring ROS1 rearrangement [167].